Medicinal use of cannabis in the United States: Historical perspectives, current trends, and future directions

Journal of Opioid Management

Volumn 5, Issue 3, 2009, Pages 153-168

  Aggarwal, Sunil K ^a   Carter, Gregory T ^b   Sullivan, Mark D ^b   ZumBrunnen, Craig ^a   Morrill, Richard ^a   Mayer, Jonathan D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Botanical medicine; Cannabinoids; Cannabis; Chronic pain; Marijuana; Opiates; Opioids

Indexed keywords

ACETYLSALICYLIC ACID; AJUMELIC ACID; ALIZAPRIDE; CANNABINOID DERIVATIVE; CANNABIS; DOMPERIDONE; DRONABINOL; ENDOCANNABINOID; LEVONANTRADOL; NABILONE; NABIXIMOL; OPIATE; PLACEBO; PROCHLORPERAZINE; UNCLASSIFIED DRUG;

ANOREXIA; ANTIEMETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; CACHEXIA; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; DEPERSONALIZATION; DISEASE ASSOCIATION; DROWSINESS; DRUG INDUSTRY; DRUG OVERDOSE; DYSPHORIA; DYSPNEA; EPILEPSY; FOOD AND DRUG ADMINISTRATION; GILLES DE LA TOURETTE SYNDROME; GLAUCOMA; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HUMAN; INTRACTABLE PAIN; INTRAOCULAR PRESSURE ABNORMALITY; MEDICAL INFORMATION; MEDICAL PRACTICE; MEDICAL SOCIETY; MIGRAINE; MULTIPLE SCLEROSIS; MYOFASCIAL PAIN; NAUSEA; NEUROPATHIC PAIN; NEUROPROTECTION; PAIN; PAIN THRESHOLD; PANIC; PATIENT COUNSELING; PSYCHOSIS; REVIEW; SPASTICITY; SPINAL CORD INJURY; TACHYCARDIA; TRANQUILIZING ACTIVITY; UNITED STATES; VOMITING;

EID: 68349127502     PISSN: 15517489     EISSN: None     Source Type: Journal    
DOI: 10.5055/jom.2009.0016     Document Type: Review

References (108)

1. Hanus LO: Pharmacological and therapeutic secrets of plant and brain (endo)cannabinoids. Med Res Rev. 2009; 29: 213-271.
2. Vettor R, Pagotto U, Pagano C, et al.: Here, there and everywhere: The endocannabinoid system. J Neuroendocrinol. 2008; 20: 4-7. (Pubitemid 351552668)
3. Pacher P, Batkai S, Kunos G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev. 2006; 58: 389-462. (Pubitemid 44394908)
4. Wang T, Collet J, Shapiro S, et al.: Adverse effects of medical cannabinoids: A systematic review. CMAJ. 2008; 178: 1669-1678. (Pubitemid 351899653)
5. Rocha FCM, Oliveira LMQR, Da Silveira DX: Therapeutic use of Cannabis saliva on chemotherapy-induced nausea and vomiting among cancer patients: Systematic review and meta-analysis. Eur J Cancer Care. 2008; 17: 431-443.
6. Ben Amar M: Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol. 2006; 105: 1-25.
7. Bagshaw SM, Hagen NA: Medical efficacy of cannabinoids and marijuana: A comprehensive review of the literature. J Palliat Care. 2002; 18: 111-122.
8. Musty RE, Rossi R: Effects of smoked cannabis and oral Δ9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials. J Cannabis Ther. 2001; 1: 29-56.
9. World Health Organization: World Health Statistics 2008. Available at www.who.int/whosis/whostat/EN-WHS08-Full.pdf. Accessed April 28, 2009.
10. Label for Marinol®. Label approved on June 21, 2006 for MARINOL, NDA no. 018651. Available at www.fda.gov/cder/foi/label/2006/018651s025s026lbl.pdf. Accessed April 28, 2009.
11. Dronabinol approval history 2008. Available at www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName= MARINOL. Accessed April 28, 2009.
12. Label for Cesamet®. Label approved on May 15, 2006 for CESAMET, NDA no. 018677. Available at www.fda.gov/cder/foi/label/2006/018677s011lbl.pdf. Accessed April 28, 2009.
13. Nabilone approval history, 2008. Available at www.accessdata.fda.gov/ scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Overview&DrugName= CESAMET. Accessed April 28, 2009.
14. NCT00530764. A study of Sativex® for pain relief in patients with advanced malignancy (SPRAY), 2008. Available at http://clinicaltrials.gov/ct2/ show/NCT00530764. Accessed April 28, 2009.
15. Sativex® Health Canada, 2008. Available at http://www.gencat.cat/ salut/depsalut/pdf/sativfitec.pdf.
16. Sativex® fact sheet 2008. Available at www.hc-sc.gc.ca/dhp-mps/ prodpharma/notices-avis/conditions/sativex-fs-fd-091289-eng.php. Accessed April 28, 2009.
17. "What is Sativex?" Updated December 13, 2007. Available at www.mssociety.org.uk/about-ms/treatments/sativex.html. Accessed April 28, 2009.
18. Catalan government reports positive outcome of sativex access programme, April 9, 2008. Available at http.//production.investis.com/gwp/pressreleases/ currentpress/2008-04-09/. Accessed April 28, 2009.
19. NCT00682929. Cannabis for MS Spasticity study, 2008. Available at http://clinicaltrials.gov/ct2/show/NCT00682929. Accessed April 28, 2009.
20. NCT00308555. Opioid and cannabinoid pharmacokinetic interactions: A pilot study, 2008. Available at http://clinicaltrials.gov/ct2/show/NCT00308555. Accessed April 28, 2009.
21. Ellis RJ, Toperoff W, Vaida F, et al.: Smoked medicinal cannabis for neuropathic pain in HIV: A randomized, crossover clinical trial. Neuropsychopharmacology. 2009; 34(3): 672-680.
22. Wilsey B, Marcotte T, Tsodikov A, et al.: A randomized, placebo-controlled, crossover trial of cannabis cigarettes in neuropathic pain. J Pain. 2008; 9: 506-521.
23. Corey-Bloom J, Wolfson T, Gamst A, et al.: Short-term effects of medicinal cannabis on spasticity in multiple sclerosis. 60th Annual Meeting of the American Academy of Neurology, Chicago, IL, 2008. Available at www.cmcr.ucsd.edu/geninfo/jcb-aan-poster.pdf Accessed April 28, 2009.
24. Abrams DI, Jay CA, Shade SB, et al.: Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology. 2007; 68: 515-521.
25. Abrams DI, Vizoso HP, Shade SB, et al.: Vaporization as a smokeless cannabis delivery system: A pilot study. Clin Pharmacol Ther. 2007; 82: 572-578.
26. Haney M, Gunderson EW, Rabkin J, et al.: Dronabinol and marijuana in HIV-positive marijuana smokers. Caloric intake, mood, and sleep. J AcquirImmune Defic Syndr. 2007; 45: 545-554. (Pubitemid 47294927)
27. Wallace M, Schulteis G, Atkinson JH, et al.: Dose-dependent effects of smoked cannabis on capsaicin-induced pain and hyperalgesia in healthy volunteers. Anesthesiology. 2007; 107: 785-796. (Pubitemid 351325971)
28. Haney M, Rabkin J, Gunderson E, et al.: Dronabinol and marijuana in HIV(+) marijuana smokers: Acute effects on caloric intake and mood. Psychopharmacology. 2005; 181: 170-178. (Pubitemid 41440928)
29. Abrams DI, Hilton JF, Leiser RJ, et al.: Short-term effects of cannabinoids in patients with HIV-1 infection. A randomized, placebo-controlled clinical trial. Ann Intern Med. 2003; 139: 258-266.
30. Söderpalm AH, Schuster A, de Wit H: Antiemetic efficacy of smoked marijuana: Subjective and behavioral effects on nausea induced by syrup of ipecac. Pharmacol Biochem Behav. 2001; 69: 343-350. (Pubitemid 32758716)
31. Abrams D, Leiser R, Shade S, et al.: Short-term effects of Cannabinoids on HIV-1 viral load. [abstract no. LbPeB7053]. Poster, XIII International AIDS Conference in Durban, South Africa. July 9-14, 2000; 13: 45.
32. Greenwald MK, Stitzer ML: Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend. 2000; 59: 261-275.
33. Greenberg HS, Werness SAS, Pugh JE, et al.: Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther. 1994; 55: 324-328.
34. Carter GT, Weydt P, Kyashna-Tocha M, et al.: Medical marijuana: Rational guidelines for dosing. IDrugs. 2004; 7(5): 464-470.
35. Research Advisory Panel: Cannabis therapeutic research program. Report to the California Legislature, 1989. In Musty RE, Rossi R: Effects of smoked cannabis and oral Δ9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials. J Cannabis Ther. 2001; 1: 29-56.
36. Foltin RW, Fischman MW, Byrne MF: Effects of smoked marijuana on food intake and body weight of humans living in a residential laboratory. Appetite. 1988; 11: 1-14.
37. Foltin RW, Brady JV, Fischman MW: Behavioral analysis of marijuana effects on food intake in humans. Pharmacol Biochem Behav. 1986; 25: 577-582.
38. Behavioral Health Sciences Division: The Lynn Pierson therapeutic research program. Health and Environment Department: New Mexico, 1984. In Musty RE, Rossi R: Effects of smoked cannabis and oral Δ9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials. J Cannabis Ther. 2001; 1: 29-56.
39. Behavioral Health Sciences Division: The Lynn Pierson therapeutic research program. Health and Environment Department: New Mexico, 1983. In Musty RE, Rossi R: Effects of smoked cannabis and oral Δ9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials. J Cannabis Ther. 2001; 1: 29-56.
40. Board of Pharmacy, State of Tennessee: Annual report: Evaluation of marijuana and tetrahydrocannabinol in the treatment of nausea and/or vomiting associated with cancer therapy unresponsive to conventional anti-emetic therapy: Efficacy and toxicity, 1983. In Musty RE, Rossi R: Effects of smoked cannabis and oral Δ9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials. J Cannabis Ther. 2001; 1: 29-56.
41. Kutner MH: Evaluation of the use of both marijuana and THC in cancer patients for the relief of nausea and vomiting associated with cancer chemotherapy after failure of conventional anti-emetic therapy: Efficacy and toxicity, as prepared for the Composite State Board of Medical Examiners, Georgia Department of Health, by physicians and researchers at Emory University, Atlanta, 1983. In Musty RE, Rossi R: Effects of smoked cannabis and oral Δ9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials. J Cannabis Ther. 2001; 1: 29-56.
42. Department of Social Oncology, Evaluation Unit, State of Michigan: Marihuana therapeutic research project, 1982. In Musty RE, Rossi R: Effects of smoked cannabis and oral Δ9-tetrahydrocannabinol on nausea and emesis after cancer chemotherapy: A review of state clinical trials. J Cannabis Ther 2001; 1: 29-56.
43. Chang AE, Shiling DJ, Stillman RC, et al.: A prospective evaluation of delta-9 tetrahydrocannabinol as an antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer. 1981; 47: 1746-1751.
44. Merritt JC, Crawford WJ, Alexander PC, et al.: Effect of marihuana on intraocular and blood pressure in glaucoma. Ophtalmology. 1980; 87: 222-228. (Pubitemid 10130590)
45. Chang AE, Shiling DJ, Stillman RC, et al.: Delta-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high dose methotrexate. Ann Inten Med. 1979; 91: 819-824.
46. Crawford WJ, Merritt JC. Effects of tetrahydrocannabinol on arterial and intraocular hypertension. Int J Clin Pharmacol Biopharm. 1979; 17: 191-196.
47. Greenberg I, Kuehnle J, Mendelson JH, et al.: Effects of marijuana use on body weight and caloric intake in humans. Psychopharmacology. 1976; 49: 79-84.
48. Tashkin DP, Shapiro BJ, Frank IM: Acute pulmonary physiologic effects of smoked marijuana and oral A9-tetrahydrocannabinol in healthy young men. N Engl J Med. 1973; 289: 336-341.
49. Hill SY, Schwin R, Goodwin DW, et al.: Marihuana and pain. J Pharmacol Exp Ther. 1974; 188: 415-418.
50. Tashkin DP, Shapiro BJ, Frank IM: Acute effects of smoked marijuana and oral Δ9-tetrahydrocannabinol on specific airway conductance in asthmatic subjects. Am Rev Respir Dis. 1974; 109: 420-428.
51. Tashkin DP, Shapiro BJ, Lee YE, et al.: Effects of smoked marijuana in experimentally induced asthma. Am Rev Respir Dis. 1975; 112: 377-386.
52. Vachon L, Fitzgerald MX, Solliday NH, et al.: Single-dose effect of marihuana smoke: Bronchial dynamics and respiratory-center sensitivity in normal subjects. N Engl J Med. 1973; 288: 985-989.
53. Hollister LE: Hunger and appetite after single doses of marihuana, alcohol, and dextroamphetamine. Clin Pharmacol Ther. 1971; 12: 44-49.
54. 53- Aggarwal SK, Kyashna-Tocha M, Carter GT: Dosing medical marijuana: Rational guidelines on trial in Washington State. MedGenMed. 2007; 9(3): 52. (Pubitemid 47394090)
55. Russo E, Mathre ML, Byrne A, et al.: Chronic cannabis use in the compassionate investigational new drug program: An examination of benefits and adverse effects of legal clinical cannabis. J Cannabis Ther 2001; 2: 3-57. (Pubitemid 34467431)
56. US Department of Justice Drug Enforcement Administration: In the matter of Lyle E. Craker, PhD. Arlington, VA. Docket No. 05-16: 1167, 2005.
57. 21 USC Sec. 812 01/22/02. Available at www.usdoj.gov/dea/pubs/csa/812. htm. Accessed April 28, 2009.
58. MAPS Marijuana Research. 2008. Available at www.maps.org/mmj/mjabrams. html. Accessed April 28, 2009.
59. Randall RC, O'Leary AM. Marijuana Rx: The Patients' Fight for Medicinal Pot. New York: Thunder's Mouth Press, 1998.
60. Earlywine M: Understanding Marijuana: A New Look at the Scientific Evidence. New York: Oxford University Press, 2002.
61. Abel EL: Marihuana, the First Twelve Thousand Years. New York: Plenum Press, 1980.
62. O'Shaughnessy WB: On the preparations of the Indian hemp, or gunjah (Cannabis indica); their effects on the animal system in health, and their utility in the treatment of tetanus and other con- vulsive diseases. Trans Med Phys Soc Bengal 1838-1840; 71-102: 421-461. Available at www.mikuriya.com/s1-1. pdf. Accessed April 28, 2009.
63. Baker D, Pryce G, Giovannoni G, et al.: Therapeutic potential of cannabis. Lancet Neurol. 2003; 2: 291-298.
64. Joy JE, Watson SJ, Benson JA (eds.): Marijuana and Medicine: Assessing the Science Base. Washington, DC: National Academy Press, 1999.
65. Proceedings of the 2008 MSS Annual Meeting. 2008. Available at www.ama-assn.org/ama1/pub/upload/mm/15/a-08-mss-proceedings.pdf. Accessed April 28, 2009.
66. Medical marijuana endorsements and statements of support. 2008. Available at http://www.mpp.org/assets/pdfs/download-materials/Mmj-Endorsements-0908- NOLOGO.pdf. Accessed April 28, 2009.
67. Carter GT, Mirken B: Medical marijuana: Politics trumps science at the FDA. MedGenMed. 2006; 8(2): 46.
68. General Comment No. 14. On the right to the highest attainable standard of health (Article 12 of the International Covenant on Economic, Social, and Cultural Rights); Committee on Economic, Social, and Cultural Rights; UN doc.E/C.12/2000/4, 4 July 2000.
69. Conant v Walters, 309 F.3d 629 (9th Cir 2002), cert denied (2003).
70. California medical marijuana doctors face federal, professional scrutiny. News summary of Associated Press story. Join Together, November 6, 2006, Available at www.jointogether.org/news/headlines/inthenews/2006/california- medical-marijuana.html. Accessed April 28, 2009.
71. Dr. Mikuriya's observations: 10 years of legalized medical marijuana in California. Counterpunch, November 4, 2006. Available at http://counterpunch. org/gardner11042006.html. Accessed April 28, 2009.
72. Colorado Department of Public Health and Environment. 2008. Available at www.cdphe.state.co.us/hs/Medicalmarijuana/marijuanaupdate.html. Accessed April 28, 2009.
73. Lawmaker addressing medical marijuana. Honolulu StarBulletin, February 1, 2008. Available at http://starbulletin.com/2008/02/01/news/story09.html. Accessed April 28, 2009.
74. ACLU provides forum on pain and marijuana. Missoulian, March 1, 2008. Available at www.missoulian.com/articles/2008/03/02/news/local/news03.txt. Accessed April 28, 2009.
75. Federal government stands in the way of a state-run medical marijuana distribution. Nevada Appeal, February 4, 2008. Available at www.nevadaappeal. com/article/20080204/NEWS/440177627. Accessed April 28, 2009.
76. Department of Human Services: Oregon Medical Marijuana Program (OMMP) Data, 2008. Available at http://oregon.gov/DHS/ph/ommp/data.shtml. Accessed April 28, 2009.
77. For more than 300 Rhode Islanders, marijuana provides legal relief. Providence Journal, September 9, 2007. Available at wwiv.projo.com/news/content/ medical-marijuana-09-09-07-SS6OB77.15d6f0a.html. Accessed April 28, 2009.
78. The new reefer madness: Arresting people in pain. Seattle Times, July 23, 2008. Available at http://seattletimes.nwsource.com/html/opinion/2008066765- rams23html. Accessed April 28, 2009.
79. DEA federal penalties for marijuana. 2008. Available at www.dea.gov/agency/penalties.htm. Accessed April 28, 2009.
80. Gonzales v Raich, 125 S. Ct. 2195 (2005).
81. Meade M, Earickson R: Medical Geography. New York: Guilford Press, 2000.
82. Rosenberg MW: Linking the geographical, the medical and the political in analysing health care delivery systems. Soc Sci Med. 1988; 26: 179-186.
83. Joseph AE, Phillips DR: Accessibility and Utilization: Geographical Perspectives on Health Care Delivery. New York: Harper & Row, 1984.
84. University of Washington Medical Center Policy 80.15. 2002. Guidance to Physicians Regarding Medical Marijuana, effective March 2002. Available at http://students.washington.edu/sunila/MMJ-memo-UW.pdf Accessed April 28, 2009.
85. Chapter 69.51A RCW. Medical marijuana. 2008 (most recent amendment). Available at http://apps.leg.wa.gov/RCW/default.aspx?Cite=69.51A. Accessed April 28, 2009.
86. Aggarwal S, Carter GT, Steinborn J: Clearing the air: What the latest Supreme Court decision regarding medical marijuana really means. Am J Hosp Palliat Care. 2005; 22(5): 327-329. (Pubitemid 41432856)
87. Russo EB: The role of cannabis and cannabinoids in pain management. In Weiner RS (ed.): Pain Management: A Practical Guide for Clinicians. 6th ed. New York: CRC Press, 2002.
88. Paulozzi LJ: Opioid analgesic involvement in drug abuse deaths in American metropolitan areas. Am J Public Health. 2006; 96: 1755-1757.
89. Mikuriya TH: Cannabis: A unique immunoanalgesic. Poster at the 2006 American Pain Society Meeting, San Antonio, CA.
90. Armentano P: Cannabis, mental health and context: The case for regulation. National Organization for the Reform of Marijuana Laws Health Report, 2006.
91. Erowid E: Cannabis & psychosis: A guide to current research about cannabis and mental health. Erowid Extracts. 2005; 8: 4-7.
92. Gardner D: How science is skewed to fuel fears of marijuana. The Ottawa Citizen. March 20, 2005.
93. Mirken B, Earleywine M: The cannabis and psychosis connection questioned: A comment on Fergusson et al. Addiction. 2005; 100: 714-715; author reply 715-716. (Pubitemid 40655308)
94. Advisory Council on the Misuse of Drugs: Further consideration of the classification of cannabis under the Misuse of Drugs Act 1971. London: Home Office, 2005. Available at http://drugs.homeoffice.gov.uk/publication-search/ acmd/cannabis-reclass-2005?view=Binary. Accessed April 28, 2009.
95. Advisory Council on the Misuse of Drugs: Cannabis: Classification and public health. London: Home Office, 2008. Available at http://drugs.homeoffice. gov.uk/publication-search/acmd/acmd-cannabis-report-2008?view=Binary. Accessed April 28, 2009.
96. Hashibe M, Morgenstern H, Cui Y, et al.: Marijuana use and the risk of lung and upper aerodigestive tract cancers: Results of a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 2006; 15(10): 1829-1834.
97. Data also presented in: Tashkin DP, Zhang Z, Greenland S, et al.: Marijuana use and lung cancer: Results of a case-control study. Presented at the American Thoracic Society International Conference, San Diego, CA, May 19-24, 2006.
98. Data also presented in: Morgenstern H, Greenland S, Zhang Z, et al.: Marijuana use and cancers of the lung and upper aerodigestive tract: Results of a case-control study. Presented at the International Cannabinoid Research Society (ICRS) 15th Annual Symposium on the Cannabinoids, Clearwater Florida, June 24-27, 2005.
99. Melamede R: Cannabis and tobacco smoke are not equally carcinogenic. Harm Reduction J. 2005; 2: 21.
100. Carter GT, Ugalde V: Medical marijuana: Emerging applications for the management of neurologic disorders. Phys Med Rehabil Clin N Am. 2004; 15: 943-954.
101. Russo E, Guy G: A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses. 2006, 66(2): 234-246. (Pubitemid 41773895)
102. McPartland JM, Pruitt PL: Side effects of pharmaceuticals not elicited by comparable herbal medicines: The case of tetrahydrocannabinol and marijuana. Altern Ther Health Med. 1999; 5: 57-62.
103. Carter GT, Weydt P: Cannabis: Old medicine with new promise for neurological disorders. Curr Opin Investig Drugs. 2002; 3(3): 437-440.
104. Amtmann D, Weydt P, Johnson KL, et al.: Survey of cannabis use in patients with amyotrophic lateral sclerosis. Am J Hosp Palliat Care. 2004; 21(2): 95-104. (Pubitemid 38560946)
105. Carter GT, Rosen BS: Marijuana in the management of amyotrophic lateral sclerosis. Am J Hosp Palliat Care. 2001; 18(4): 264-270.
106. Fusar-Poli P, Crippa JA, Bhattacharyya S, et al.: Distinct effects of Δ9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Arch Gen Psychiatry. 2009, 66: 95-105.
107. Gieringer DH, Rosenthal E, Carter GT (eds.): Marijuana Medical Handbook: Practical Guide to Therapeutic Uses of Marijuana. Oakland, CA: Quick American Press, 2008: 174-177.
108. Gorman DM, Huber CJ: Do medical cannabis laws encourage cannabis use? Int J Drug Policy. 2007; 18(3): 160-167.